focus -WSS

focus

author：entertainment 2025-09-27 19:38:08 - browse：4158

Sutter Health Palo Alto Medical Foundation facilities. health tech coverage from STAT — Adobe

When Sutter Health was on trial for anticompetitive conduct in 2022, the San Francisco jury missed out on some crucial details. They didn’t hear, for example, how its former finance chief said the system would make an extra $200 million per year by making insurers contract with all of its hospitals instead of just a few. Or how its former CEO said, “Related to the health plans, we force them to pay us more.”

That evidence was indeed relevant, and the judge erred by not allowing it to be presented during the month-long trial that concluded in March 2022, a U.S. appeals court wrote in its ruling on Tuesday. The Ninth Circuit panel overturned Sutter’s win in the class-action case alleging that Sutter used its market power to drive up health care costs across the region by more than $400 million. Tuesday’s decision means the case will likely get a second trial.

“Effectively, the appellate court said the jury was tainted,” said Matthew Cantor, lead counsel for the plaintiffs. “So the jury’s verdict is discarded.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Colorectal cancer study finds potential in overlooked immune cell

WSS

Physician executives need more than on

Colorectal cancer study finds potential in overlooked immune cell

VC firm General Catalyst wants to buy a health system

NEJM study link tiny plastics in blood vessels to heart problems

The drug industry has found itself all alone in Washington

Why age limits for politicians are a terrible idea

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Bristol 'take

Trump demands the U.S. pay no more for drugs than other countries … again

Liquid biopsy for lung cancer is launched by Delfi

In age of alternative facts, a scholarly course on calling out crap

NEJM study link tiny plastics in blood vessels to heart problems

As demand for Covid shots wanes, Moderna seeks its next success

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

focus

IVF, abortion rights issues kick off Biden’s State of the Union

FDA panel signals lack of confidence in Amgen cancer drug data

FDA authorizes Novavax’s updated Covid

AI can decode, harness the power of the humane immune system

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Why Charlie Gard's case is so disturbing to Americans

leisure time

leisure time

focus

leisure time